AQST Stock News & Catalysts – Aquestive Therapeutics

FEATURED

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

New

WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful

Summary

Nov 9, 2026, 7:00 AM ·Globe Newswire

RECENT

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful

Nov 5, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if

Nov 3, 2026, 4:01 PM ·Globe Newswire

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET

WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful

Oct 27, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned

Oct 15, 2026, 7:00 AM ·Globe Newswire

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient

Oct 14, 2026, 6:50 AM ·Globe Newswire

Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (NASDAQ:AQST) investors that the firm is investigating potential legal claims arising from alleged

Oct 7, 2026, 9:30 AM ·PRNewswire

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of

Sep 29, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline

Sep 17, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement

Sep 1, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues pre-launch medical

Aug 11, 2026, 4:01 PM ·Globe Newswire

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK

Aug 10, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement

Jul 29, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement

Jul 7, 2026, 7:00 AM ·Globe Newswire

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the

May 13, 2026, 4:01 PM ·Globe Newswire

Aquestive Therapeutics, Inc. AQST · News